Evidence map›Paper›PMID 21783174›Full record

ArticleBiological psychiatry2011

Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation.

David Hessl, John M Wang, Andrea Schneider, Kami Koldewyn, Lien Le, Christine Iwahashi, Katherine Cheung, Flora Tassone, Paul J Hagerman, Susan M Rivera

Open access · greenAbstract read
In one paragraph

Article in Biological psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 2 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Emotion potentiated startle in fragile X syndrome.Journal of autism and developmental disorders · 2014
    Trial
  4. Article
  5. Article
  6. Social Communication Delay in an Unbiased Sample of Preschoolers With theJournal of speech, language, and hearing research : JSLHR · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. The Phenotypic Profile Associated With theFrontiers in psychiatry · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The other side of the coin: Hypersociability.Genes, brain, and behavior · 2019
    Review
  17. Article
  18. Review
  19. Age-related functional brain changes inNeuroImage. Clinical · 2018
    Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

David HesslMedical Investigation of Neurodevelopmental Disorders (M.I.N.D.) Institute, University of California-Davis, Medical Center, Sacramento, California 95817, USA. david.hessl@ucdmc.ucdavis.edu
John M Wang
Andrea Schneider
Kami Koldewyn
Lien Le
Christine Iwahashi
Katherine Cheung
Flora Tassone
Paul J Hagerman
Susan M Rivera
University of California, Davis · USUniversity of California Davis Medical Center · USMcGovern Institute for Brain Research · US

Funding

Restoring FMRP Phenotypes Frpm Temporal Regional and Splice- Isoforms VarationsP30HD002274 · NICHD · UNIVERSITY OF WASHINGTON · PI GURALNICK, MICHAEL J · 1985 to 2013
$33.6M
Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)RL1AG032119 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2011
$4.1M
Neuro Therapeutics Research Institute (1 of 6)UL1DE019583 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2008 to 2011
$3.0M
Neuro Therapeutics Research InstituteUL1RR024922 · NCRR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2007
$807k
Genetics and Physiology of Social Anxiety in Fragile XK23MH077554 · NIMH · UNIVERSITY OF CALIFORNIA DAVIS · PI HESSL, DAVID R · 2005 to 2009
$772k
NCRR NIH HHS UL1 RR024922NIA NIH HHS RL1 AG032119NIA NIH HHS RL1AG032119NICHD NIH HHS HD02274NICHD NIH HHS P30 HD002274NIDCR NIH HHS UL1 DE019583NIMH NIH HHS K23 MH077554NIMH NIH HHS MH078041NIMH NIH HHS MH77554NIMH NIH HHS R01 MH078041
6 · The paper itself

Abstract

backgroundThe fragile X premutation provides a unique opportunity for the study of genetic and brain mechanisms of behavior and cognition in the context of neurodevelopment and neurodegeneration. Although the neurodegenerative phenotype, fragile X-associated tremor/ataxia syndrome, is well described, evidence of a causal link between the premutation and psychiatric disorder earlier in life, clear delineation of a behavioral/cognitive phenotype, and characterization of the physiological basis of observed symptoms have been elusive.

methodsWe completed functional magnetic resonance imaging targeting the amygdala with an emotion-matching task and concurrent infrared eye tracking, FMR1 molecular genetic testing, and neuropsychological assessment in 23 men with the premutation (mean age = 32.9 years) and 25 male control subjects (mean age = 30.1 years).

resultsPremutation carriers had significantly smaller left and right amygdala volume and reduced right amygdala activation during the task relative to control subjects. Although both elevated FMR1 messenger RNA and reduced fragile X mental retardation protein (FMRP) were associated with the reduced activation, multiple regression analysis suggested that reduced FMRP is the primary factor. Premutation carriers also had higher ratings of autism spectrum symptoms than control subjects, which were associated with the reduced amygdala response.

conclusionsAlthough prior studies have emphasized a toxic gain-of-function effect of elevated messenger RNA associated with the premutation, the current results point to the role of reduced FMRP in alterations of brain activity and behavior.

Indexed as

HeterozygoteAdultAmygdalaAutistic DisorderBrainCognitionDNAEmotionsEye MovementsFragile X Messenger Ribonucleoprotein 1HumansImage Processing, Computer-AssistedIntelligence TestsMagnetic Resonance ImagingMaleMutationDNAFragile X Messenger Ribonucleoprotein 1RNA, Messenger

Identifiers

PMID21783174
PMCPMC3191264
OpenAlexW2061651717

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.